SOLV · XBRL financial data
Solventum financial statements, every fiscal year
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (SOLV's year ends in late December)
| In millions of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Revenue | 8,254 | 8,325 |
| Gross profit | 4,593 | 4,451 |
| Research and development | 775 | 739 |
| Selling, general and administrative | 2,782 | 3,080 |
| Operating income (loss) | 1,036 | 2,181 |
| Other income (expense) | (64) | (39) |
| Income tax expense (benefit) | 127 | 157 |
| Net income (loss) | 479 | 1,556 |
| Earnings per share, basic USD per share | 2.77 | 8.94 |
| Earnings per share, diluted USD per share | 2.76 | 8.88 |
| Weighted average shares, basic millions of shares | 173 | 174 |
| Weighted average shares, diluted millions of shares | 174 | 175 |
Balance sheet
CSVFiscal years (SOLV's year ends in late December)
| In millions of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Cash and cash equivalents | 762 | 878 |
| Accounts receivable | 1,044 | 1,034 |
| Inventory | 965 | 1,066 |
| Total current assets | 3,249 | 3,859 |
| Property and equipment, net | 1,622 | 1,326 |
| Right-of-use asset | 176 | 214 |
| Goodwill | 6,377 | 5,704 |
| Total assets | 14,457 | 14,294 |
| Accounts payable | 618 | 687 |
| Accrued liabilities | 272 | 435 |
| Commercial paper | 0 | 0 |
| Current portion of long-term debt | 200 | 0 |
| Total current liabilities | 2,703 | 3,136 |
| Long-term debt | 7,810 | 5,035 |
| Lease liability, non-current | 86 | 142 |
| Total liabilities | 11,498 | 9,245 |
| Retained earnings | 242 | 1,797 |
| Total stockholders' equity | 2,959 | 5,049 |
| Total liabilities and equity | 14,457 | 14,294 |
| Common shares outstanding (cover page) millions of shares | 173 | 173 |
Cash flows
CSVFiscal years (SOLV's year ends in late December)
| In millions of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Net income (loss) | 479 | 1,556 |
| Stock-based compensation | 112 | 161 |
| Depreciation and amortization | 555 | 489 |
| Net cash from operating activities | 1,185 | 369 |
| Purchases of property and equipment | 380 | 379 |
| Net cash from investing activities | (380) | 2,797 |
| Net cash from financing activities | (240) | (3,057) |
| Net change in cash | 568 | 116 |
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Quarter |
|---|---|---|---|---|---|
| Solventum | 403 | 2,209 | 227* | 170.2M | 10-QJun 30, 2026 |
| Medline | 2,321 | 7,856 | 1,025* | not reported | 10-QSep 26, 2026 |
| Hologic | 2,168 | 1,048 | 230 | 223.2M | 10-QDec 27, 2025 |
| Align Technology | 1,145 | 1,015 | 183* | 70.5M | 10-QSep 30, 2026 |
| West Pharmaceutical Services | 464 | 875 | 190* | 69.7M | 10-QSep 30, 2026 |
| Baxter International | 1,975 | 2,976 | 558* | 517.3M | 10-QSep 30, 2026 |
| Penumbra | 254 | 410 | 42* | 39.4M | 10-QSep 30, 2026 |
| Zimmer Biomet Holdings | 400 | 2,063 | 560* | 189.3M | 10-QSep 30, 2026 |
| Insulet | 584 | 842 | 124* | 69.4M | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.